WuXi Biologics (Cayman) Inc., a company incorporated in the Cayman Islands, has announced the approval of a new grant of 64,117 restricted shares under its Restricted Share Award Scheme. The grant, approved by the Board on June 5, 2025, is subject to acceptance by the grantee. This decision aligns with the company's effort to allocate shares under the scheme, which currently has 187,681,267 restricted shares available for future grants. The Board, including independent non-executive directors, has deemed the grant as fair and reasonable, considering it beneficial for the interests of the company and its shareholders. The restricted shares are ordinary shares with a nominal value of US$1/120,000 each.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.